Journal article
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
Abstract
BackgroundVenetoclax is a first-in-class targeted therapy option that is an inducer of apoptosis in chronic lymphocytic leukemia (CLL) cells. The open-label phase III CLL14 clinical trial showed that venetoclax combined with obinutuzumab (VEN+O) is superior to obinutuzumab combined with chlorambucil in newly diagnosed patients with CLL. The aim of this study was to assess the health economic value of VEN+O for the frontline treatment of CLL in …
Authors
Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
Journal
PharmacoEconomics - Open, Vol. 7, No. 2, pp. 199–216
Publisher
Springer Nature
Publication Date
3 2023
DOI
10.1007/s41669-022-00375-x
ISSN
2509-4262